BNOX Profile
Bionomics Limited is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative therapeutics for central nervous system (CNS) disorders and cancers. The company's research is focused on developing novel drug candidates that address significant unmet medical needs in these areas. Bionomics is advancing several key programs, including BNC210, a negative allosteric modulator targeting the α7 nicotinic acetylcholine receptor. BNC210 is currently undergoing Phase 2 clinical trials for social anxiety disorder and Phase 2b trials for post-traumatic stress disorder (PTSD). This candidate aims to offer a new treatment option for these challenging mental health conditions, leveraging its unique mechanism of action to modulate receptor activity in the brain.
In addition to BNC210, Bionomics is developing BNC101, a monoclonal antibody designed to target cancer stem cells. This drug candidate has successfully completed Phase 1 clinical trials, demonstrating its potential to address cancer stem cells that are often resistant to conventional treatments. BNC101 aims to provide a novel therapeutic approach to targeting the root causes of cancer and improving treatment outcomes for patients with various types of cancer.
Another significant drug in Bionomics’ pipeline is BNC105, an anti-cancer agent currently in Phase 2 clinical trials for refractory colorectal cancer and Phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). BNC105 is designed to inhibit tumor blood vessel formation, thereby starving tumors of the necessary nutrients and oxygen they need to grow. This therapeutic approach holds promise for treating cancers that have proven resistant to existing therapies, offering hope for improved patient outcomes.
Founded in 1996 and headquartered in Eastwood, Australia, Bionomics Limited is dedicated to advancing its pipeline of drug candidates through rigorous clinical development. The company’s commitment to innovation in the treatment of CNS disorders and cancers underscores its broader mission to improve patient lives by addressing some of the most challenging and complex health conditions. Through its cutting-edge research and development efforts, Bionomics aims to bring transformative new treatments to market and make a meaningful impact on global healthcare.
|
